Loading...
PBYI logo

Puma Biotechnology, Inc.NasdaqGS:PBYI Voorraadrapport

Marktkapitalisatie US$380.6m
Prijs aandeel
US$7.51
US$5
50.2% overgewaardeerd intrinsieke korting
1Y143.8%
7D1.5%
Portefeuillewaarde
​
Bekijk

Puma Biotechnology, Inc.

NasdaqGS:PBYI Voorraadrapport

Marktkapitalisatie: US$380.6m

Puma Biotechnology (PBYI) Aandelenoverzicht

Puma Biotechnology, Inc. is een biofarmaceutisch bedrijf dat zich richt op de ontwikkeling en commercialisering van producten om de kankerzorg in de Verenigde Staten en internationaal te verbeteren. Meer informatie

Beloningen

Verhandeld tegen 69.6% onder onze schatting van de reële waarde

De winst is de afgelopen 5 jaar met 72.5% per jaar gegroeid

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 11.2% per jaar dalen.


PBYI Community Fair Values

Create Narrative

See what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
GANX logo
GANXFeatured

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake

Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
View narrative
Community Contributor
US$7.6FV • 75.1% ondergewaardeerd intrinsieke korting
5022.2%Revenue growth p.a.
3.7k
23
2
54
28d ago

Puma Biotechnology, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Puma Biotechnology
Historische aandelenkoersen
Huidige aandelenkoersUS$7.51
52 Week HoogtepuntUS$7.90
52 Week LaagUS$2.85
Bèta1.18
1 maand verandering17.53%
3 maanden verandering15.90%
1 Jaar Verandering143.83%
3 jaar verandering187.74%
5 jaar verandering-22.42%
Verandering sinds IPO-44.37%

Recent nieuws en updates

PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing

Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.

PBYI: 2026 Profitability Guidance Will Likely Fail To Support Current Pricing

Analysts have slightly adjusted their price target on Puma Biotechnology, keeping fair value around $5.00 while fine tuning inputs such as discount rate, revenue growth, profit margin, and future P/E to reflect updated assumptions about the company’s risk profile and earnings potential. What's in the News Puma Biotechnology issued new earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million, with an expected net loss of US$8 million to US$10 million (company guidance).

PBYI: 2026 Guidance Will Likely Fail To Justify Current Pricing

Analysts have modestly adjusted their price target on Puma Biotechnology, reflecting small refinements to assumptions around the discount rate, revenue growth, profit margins, and forward P/E rather than a major shift in the outlook. What's in the News Puma Biotechnology issued earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million (Key Developments).

PBYI: Index Inclusion Will Likely Fail To Offset Weak Revenue Outlook

Analysts have trimmed their price target on Puma Biotechnology to $5.00 from $5.00 in response to updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E. These changes leave the fair value estimate effectively unchanged.

Recent updates

PBYI: 2026 Profit Outlook Will Likely Fail To Justify Current Pricing

Analysts have adjusted their price target on Puma Biotechnology slightly, with the updated fair value moving to $5.00. This reflects refreshed views on the discount rate, long-term revenue growth, profit margins, and future P/E assumptions.

PBYI: 2026 Profitability Guidance Will Likely Fail To Support Current Pricing

Analysts have slightly adjusted their price target on Puma Biotechnology, keeping fair value around $5.00 while fine tuning inputs such as discount rate, revenue growth, profit margin, and future P/E to reflect updated assumptions about the company’s risk profile and earnings potential. What's in the News Puma Biotechnology issued new earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million, with an expected net loss of US$8 million to US$10 million (company guidance).

PBYI: 2026 Guidance Will Likely Fail To Justify Current Pricing

Analysts have modestly adjusted their price target on Puma Biotechnology, reflecting small refinements to assumptions around the discount rate, revenue growth, profit margins, and forward P/E rather than a major shift in the outlook. What's in the News Puma Biotechnology issued earnings guidance for the first quarter of 2026, projecting net product revenue of US$36 million to US$39 million and royalty revenue of US$2 million to US$3 million, for total revenue of US$38 million to US$42 million (Key Developments).

PBYI: Index Inclusion Will Likely Fail To Offset Weak Revenue Outlook

Analysts have trimmed their price target on Puma Biotechnology to $5.00 from $5.00 in response to updated assumptions regarding discount rates, revenue growth, profit margins, and future P/E. These changes leave the fair value estimate effectively unchanged.

PBYI: Index Addition And Refined Assumptions Will Still Limit Upside Potential

Analysts have adjusted their price target on Puma Biotechnology to reflect an updated fair value of $5.00, a slightly lower discount rate of 7.25%, almost unchanged revenue growth at about 97%, a stable profit margin near 11.02%, and a marginally different future P/E of roughly 13.33x, indicating a largely intact valuation framework with only fine tuning to their assumptions. What's in the News Puma Biotechnology, Inc.

PBYI: Index Inclusion And Higher Multiple Will Likely Fail To Support Upside

Analysts have raised their price target on Puma Biotechnology to $5.00 from $3.50, citing updates to fair value estimates, discount rate assumptions, and expected future P/E levels. What's in the News Puma Biotechnology, Inc.

PBYI: Higher 2025 Guidance And Index Addition Will Not Sustain Current Optimism

Analysts have slightly adjusted their price target on Puma Biotechnology, citing modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these changes translate into a small refinement in estimated fair value rather than a major reset in outlook.

PBYI: Higher 2025 Guidance And Index Inclusion Will Still Look Overpriced

Analysts have lifted their price targets on Puma Biotechnology, citing updates to their models that reflect a fair value estimate of $5.00, adjusted discount rates, revised revenue growth assumptions of about 1% instead of a 3% decline, higher projected profit margins of around 10% compared with about 3%, and a lower assumed future P/E multiple near 14 versus about 37. What's in the News Puma Biotechnology, Inc.

PBYI: Raised 2025 Guidance Will Still Fail To Support Current Optimism

Analysts have modestly trimmed their price target on Puma Biotechnology to reflect a slightly lower future earnings multiple, even as estimates for fair value and long term growth remain largely unchanged. What's in the News Puma Biotechnology has been added to the NASDAQ Biotechnology Index, increasing its visibility among biotech-focused investors (index announcement).

PBYI: 2025 Revenue Guidance Will Fail To Justify Current Optimism

Analysts have modestly adjusted their price target on Puma Biotechnology higher, now seeing slightly improved valuation support in light of stable fair value estimates and marginally lower perceived risk in the companys long term outlook. What's in the News Puma Biotechnology issued new fourth quarter 2025 guidance, projecting total revenue between $67 million and $70 million and net income of $9 million to $11 million (company guidance).

With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case

Dec 09
With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case

PBYI: Rising Discount Rate Will Undermine Earnings Momentum In 2025

Analysts have slightly lowered their price target for Puma Biotechnology, citing marginal revisions in key financial estimates. This resulted in a new target of $3.50 per share, which remains unchanged from the previous assessment.

Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit

Nov 13
Puma Biotechnology's (NASDAQ:PBYI) Shareholders May Want To Dig Deeper Than Statutory Profit

Puma Biotechnology: Step By Step In Making A Transition

Nov 10

PBYI: Rising Discount Rate And Weak Revenue Outlook Will Pressure Earnings

Analysts have raised their price target for Puma Biotechnology from $3.00 to $3.50, citing improved revenue growth projections and stronger expected profit margins. What's in the News Puma Biotechnology issued new earnings guidance for the fourth quarter of 2025, projecting total revenue between $67 million and $70 million, and net income between $9 million and $11 million (Key Developments).

Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Oct 18
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 26% Though Its Price And Business Still Lag The Market

Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?

Sep 11
Does Puma Biotechnology (NASDAQ:PBYI) Have A Healthy Balance Sheet?

Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market

Aug 12
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market

We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease

Aug 09
We Ran A Stock Scan For Earnings Growth And Puma Biotechnology (NASDAQ:PBYI) Passed With Ease

Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth

May 20
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth

Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential

Apr 11

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%

Mar 10
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 26%
User avatar

Alisertib Trials And International NERLYNX Approvals Will Expand Market, But Single Product Dependence And Safety Concerns Could Limit Gains

Strategic collaborations and regulatory approvals in international markets are expected to drive global revenue growth and increase overall sales.

Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price

Jan 14
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Dec 16

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Rendement voor aandeelhouders

PBYIUS BiotechsUS Markt
7D1.5%-2.2%0.6%
1Y143.8%30.4%28.7%

Rendement versus industrie: PBYI overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 30.4 % opleverde.

Rendement versus markt: PBYI overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.

Prijsvolatiliteit

Is PBYI's price volatile compared to industry and market?
PBYI volatility
PBYI Average Weekly Movement9.9%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.3%

Stabiele aandelenkoers: PBYI heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van PBYI is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2010179Alan Auerbachwww.pumabiotechnology.com

Puma Biotechnology, Inc., een biofarmaceutisch bedrijf, richt zich op de ontwikkeling en commercialisering van producten om de kankerzorg in de Verenigde Staten en internationaal te verbeteren. Het bedrijf biedt NERLYNX aan, een orale versie van neratinib dat wordt gebruikt voor de behandeling van volwassen patiënten met HER2-overexpressie/versterkte borstkanker in een vroeg stadium en gevorderde of gemetastaseerde HER2-positieve borstkanker in combinatie met capecitabine. Het bedrijf ontwikkelt ook alisertib, een kleine molecule remmer van aurora kinase A voor de behandeling van hormoonreceptor positieve borstkanker, triple negatieve borstkanker, kleincellige longkanker en hoofd-halskanker.

Puma Biotechnology, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Puma Biotechnology zich tot de beurswaarde?
PBYI fundamentele statistieken
MarktkapitalisatieUS$380.56m
Inkomsten(TTM)US$31.11m
Inkomsten(TTM)US$228.37m
12.3x
Koers/Winstverhouding
1.7x
P/S-verhouding

Is PBYI overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PBYI resultatenrekening (TTM)
InkomstenUS$228.37m
Kosten van inkomstenUS$58.16m
BrutowinstUS$170.21m
Overige uitgavenUS$139.10m
InkomstenUS$31.11m

Laatst gerapporteerde inkomsten

Dec 31, 2025

Volgende inkomensdatum

May 07, 2026

Winst per aandeel (EPS)0.61
Brutomarge74.53%
Nettowinstmarge13.62%
Schuld/Eigen Vermogen Verhouding17.3%

Hoe presteerde PBYI op de lange termijn?

Bekijk historische prestaties en vergelijking

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/04/30 16:35
Aandelenkoers aan het einde van de dag2026/04/30 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Puma Biotechnology, Inc. wordt gevolgd door 13 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Geoffrey MeachamBofA Global Research
Yigal NochomovitzCitigroup Inc
Paul ChoiGoldman Sachs